OCT 12, 2017 12:00 PM PDT

Live-single-cell phenotypic biomarkers measured from primary biopsy samples: An emerging class of biomarkers toward the development of precision diagnostics and the discovery and development

Speaker
  • Co-Founder and CEO, Cellanyx
    Biography
      As CEO of Cellanyx, Ashok is commercializing a biopsy-on-a-chip platform technology that enables precision diagnostics and personalized therapeutics for prostate and breast cancers.

      Cellanyx is leveraging the unique capability to rapidly analyze live patient-biopsy-cells on an ex vivo platform powered by microfluidics, phenotypic biomarkers, machine vision, and machine learning.

      Cellanyx's first-in-class platform is poised to dramatically disrupt the diagnostics and therapeutic tools markets that historically have been limited by static formalin-fixed cells, bulk and noisy genomic analysis, irrelevant cell line cultures and cumbersome animal models.

      Ashok developed Cellanyx's core technology during an academic career researching topics including multidrug resistance and matrix-biology. A Fellow of Startup Leadership Boston, Ashok combines his background in biophysics with expertise in business on project management, operations, team development, entrepreneurship and raising capital.

      Passionate about translating basic scientific discoveries into therapeutic gains, and engaged in oncology research since 1996, Ashok is exceptionally motivated to create meaningful value for patients, physicians, payers, and investors.

      Ashok enjoys collaborating with executives, clinicians, engineers, and scientists to advance our understanding of biological processes, promote discovery, develop clinically actionable technologies, and create sustainable clinical and therapeutic value.

      Ashok began his scientific training at the National Institutes of Health (NIH). Advised by two Nobel Laureates, Ashok received his S.B. in Biology from MIT and Ph.D. from Columbia University. Raised in Potomac, Maryland, Ashok is a lifelong tennis player and new father, appreciating their respective emphases on preparation, dedication, stamina, and good hands.

    Abstract

    The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by marked tumor heterogeneity and diverse molecular signatures. Although thousands of biomarkers have been described, only a very small number have been successfully translated into clinical use. Undoubtedly, there is need for rapid, quantitative, and more cost effective biomarkers for tumor diagnosis and prognosis, to allow for better risk stratification and aid clinicians in making personalized treatment decisions.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    OCT 12, 2017 12:00 PM PDT

    Live-single-cell phenotypic biomarkers measured from primary biopsy samples: An emerging class of biomarkers toward the development of precision diagnostics and the discovery and development


    Specialty

    Antibodies

    Virology

    Immunology

    Dna Sequencing

    Personalized Medicine

    Clinical Diagnostics

    Immunity

    Cancer Diagnostics

    Immunotherapy

    Bioinformatics

    Flow Cytometry

    Immuno-Oncology

    Gene Expression

    Dna

    Big Data

    Geography

    Europe100%

    Registration Source

    Website Visitors100%

    Job Title

    Student100%

    Organization

    Academic Institution100%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more